Healthcare in Thoughts from the Centre
Voice activated health care: Ready for prime time?
By Mark Steedman, PhD, Research Manager, Centre for Health Solutions
“Alexa… Volume up!”
Like many children his age, my four-year old nephew loves the Frozen soundtrack, and he recently figured out how to turn up the volume from anywhere in the room without having to be close to the speaker. He uses the voice assistant that’s always on and always listening.
Time to Talk about mental health and resilience in children and young people
By Elizabeth Hampson, Director, Monitor Deloitte
Yesterday was Time to Talk Day (7th February) – a day to encourage everyone in the UK to talk about mental health.1 This week is also Child and Adolescent Mental Health Week (4-10 February) and, in view of my interests in mental health and wellbeing, this week’s blog provides an overview of recent developments and insights about mental health and resilience in children and young people.
The future awakens: how have our life sciences predictions fared in 2018
By Karen Taylor, Director, Centre for Health Solutions
Last week we provided an update on the three health care predictions from our November 2017 report - The future awakens: Life Sciences and health care predictions 2022. As promised, this week’s blog reviews developments during 2018 on the three predictions that are more life sciences focused and what we might expect to see in 2019.
The future awakens: how have our health care predictions fared in 2018
By Karen Taylor, Director, Centre for Health Solutions
As 2019 gets firmly underway I thought it would be interesting to revisit the six predictions in our November 2017 report, The future awakens: Life Sciences and health care predictions 2022, examine relevant developments in 2018 and consider what might happen in 2019. Over the past 14 months or so, the scale of change is escalating at such a pace that some of the predictions are closer to being realised that initially anticipated, while others may well be overtaken by events. While the predictions are relevant to all stakeholders across health care and life sciences, I have split them into two groups, the three more health care focussed ones are the subject of this week’s blog and next week will be the turn of our three more life sciences focused, ones.
Patient access to innovative medicine in Europe: A collaborative and value-based approach
By Elizabeth Hampson, Director, Monitor Deloitte and Amen Sanghera, Centre for Health Solutions
This week, we launched our report Patient access to innovative medicine in Europe: A collaborative and value-based approach, which examines the challenges European payers and the pharma industry are facing in funding and bringing the latest innovations to market. Moreover, the report also looks at how key industry stakeholders can work in innovative ways to ensure patients have access to the latest medical innovations.
As our parents age, health care stakeholders should determine how to connect with them…and with us (their caregivers)
By Claudia Douglass, Managing Director, Deloitte Consulting LLP
This week’s blog, by Claudia Douglas a Managing Director within the Deloitte US firm, first appeared on the US Center for Health Solutions blog site.1 The blog looks at how health care stakeholders can better connect with patients and carers who are unengaged with technological solutions and the benefits they can provide.
My Take: Highlights from the 2018 FT Conference panel discussion on the potential for a successful life sciences economy in the UK
By John Haughey, Deloitte Industry Leader, Life Sciences & Health Care
Earlier this month I had the pleasure of chairing a panel of life science experts at the Global Financial Times Pharmaceutical and Biotechnology conference.1 The conference brought together some of our industry’s leading minds to discuss the commercial conundrums of disease prevention, the transformational impact of advanced gene and cell therapies and the hope and hype of patient-centricity. The discussion topic for my panel was - ‘Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy’, and was focused on the UK’s Industrial Strategy and in particular the UK’s sector deal for life sciences.2 In this week’s blog I wanted to share some of my key takeaways from our animated and insightful discussion.
PFI/PF2 no more – How will the NHS Transform its Estate?
By Claire O’Shaughnessy and James Millar
The NHS is transforming how it delivers its services, but one key aspect to enabling this is the need for significant investment in its Estate. According to Sir Robert Naylor’s report last year, the NHS Estate ranges from world class to poorly utilised and not fit for purpose.1 Moreover, Sir Robert estimated that capital requirements could amount to around £10bn. This investment cannot be delivered through public sector funding alone. However, the Chancellor’s announcement in Budget 2018 that there will be no more Private Finance Initiative (PFI)/Private Finance 2 (PF2) Projects, this cuts off a historically well used option for enabling capital investment in the NHS.2 So what next? There are a myriad of potential solutions, and it will require a combination of traditional and innovative approaches to ensure Estates play their part in the transformation of the NHS.
Bright future: A new vision for eye health
By Mark Steedman, PhD. Research Manager, Centre for Health Solutions
This week’s blog is the third in our series focusing on eye health, which we developed in support of a global policy report that was launched this week at the World Innovation Summit for Health (WISH). Our first blog in the series focused on glaucoma, while our second examined new treatments for age-related macular degeneration (AMD). This latest blog focuses on the main findings and recommendations of the full report Bright future: A new vision for eye health.
A bold future for life sciences regulation: Predictions 2025
By Karen Taylor, Director, Centre for Health Solutions
Following our 2014 and 2017 Life Science and Health Care Predictions reports, ‘A bold future?’ and ‘The future awakens’, this week we launched our third predictions report, A bold future for Life Sciences Regulation: Predictions 2025. This year’s report presents an unashamedly optimistic view on what Life Sciences regulation might look like in 2025 if both life science companies and regulators were to work more collaboratively, embrace disruptive technologies, and acquire new skills and talent. We argue that this would improve not only the productivity of the regulators and industry but also provide patients with access to the latest medical innovation much sooner. We also imagine through a series of ‘portraits’ how a regulator, company and patient might behave in 2025. This week’s blog provides an overview of the four predictions presented in our future of regulation report and examples of the evidence today that enable us to predict a bold future for life sciences regulation in 2025.